Global Human Immunodeficiency Virus (HIV) Market

Table of Contents

1. Introduction
   1.1 Key Take-aways
   1.2 Report Description
   1.3 Markets Covered
   1.4 Research Methodology
   1.5 Stakeholders

2. Summary

3. Disease Overview
   3.1 Epidemiology

4. Current Scenario
   4.1 Market by Products
       4.1.1 Key Brands
             4.1.1.1 Truvada
                     4.1.1.1.1 Brand Name
                     4.1.1.1.2 Active Ingredient
                     4.1.1.1.3 Mechanism of action
                     4.1.1.1.4 Dosage form (s)
                     4.1.1.1.5 Latest Sales Figures
                     4.1.1.1.6 Launch Date/Year
                     4.1.1.1.7 Patent
(All the above attributes under Truvada will be covered for
the brands mentioned below)
             4.1.1.2 Atripla
             4.1.1.3 Kaletra
             4.1.1.4 Reyataz
             4.1.1.5 Sustiva
       4.1.2 Key Molecules
             4.1.2.1 Efavirenz
                     4.1.2.1.1 Trade Name
                     4.1.2.1.2 Active Ingredient
                     4.1.2.1.3 Mechanism of action
                     4.1.2.1.4 Dosage form (s)
                     4.1.2.1.5 Latest Sales Figures
                     4.1.2.1.6 Expected Launch Date/Year
                     4.1.2.1.7 Patent
(All the above attributes under Efavirenz will be covered for the molecules mentioned below)
             4.1.2.2 Emtricitabine
             4.1.2.3 Tenofovir
             4.1.2.4 Ritonavir
             4.1.2.5 Lopinavir
             4.1.2.6 Atazanavir
   4.2 Market by Mechanism of Action (MOA)
       4.2.1 Vaccines
       4.2.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       4.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       4.2.4 Protease Inhibitors (PIs)
       4.2.5 Viral Fusion (or Entry) Inhibitors
       4.2.6 HIV Integrase Strand Transfer Inhibitors
       4.2.7 CCR5 Receptor Antagonists
   4.3 Market by Geography
       4.1.1 USA
       4.1.2 Europe (EU5)
       4.1.3 Russia & CIS countries
       4.1.4 Brazil
       4.1.5 India
       4.1.6 China
       4.1.7 SouthAfrica
       4.1.8 Turkey
   4.4 Competitive landscape
   4.5 Company profiles
       4.5.1 GlaxoSmithKline
       4.5.2 Abbott Laboratories
       4.5.3 Gilead Sciences
       4.5.4 Bristol-Myers Squibb
       4.5.5 Pfizer

5. Pipeline Analysis
   5.1 Pipeline by Phase
       5.1.1 Lead Optimization/Discovery
       5.1.2 Preclinical
       5.1.3 Phase I
       5.1.4 Phase II
       5.1.5 Phase III
       5.1.6 Pending Approval
       5.1.7 Approved
       5.1.8 Discontinued
   5.2 Molecules by Phase & their profiles
       5.2.1 TMC278
             5.2.1.1 Investigational Name
             5.2.1.2 Active Ingredient
             5.2.1.3 Mechanism of Action
             5.2.1.4 Dosage form (s)
             5.2.1.5 Sales forecast
             5.2.1.6 Expected Launch
(All the above attributes under TMC278 be covered for the
pipeline molecules mentioned below)
       5.2.2 Elvitegravir
       5.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir
       5.2.4 Racivir
       5.2.5 Apricitabine
       5.2.6 Tesamorelin
       5.2.7 MPC 4326
       5.2.8 S/GSK1265744
       5.2.9 UK-453061
       5.2.10 Quad Pill (tenofovir + emtricitabine + elvitegravir + GS 9350)
   5.3 HIV therapeutics Pipeline share by Mechanism of Action (MOA)
       5.3.1 Vaccines
       5.3.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       5.3.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       5.3.4 Protease Inhibitors (PIs)Hemispherx Biopharma
       5.3.5 Viral Fusion (or Entry) Inhibitors
       5.3.6 HIV Integrase Strand Transfer Inhibitors
       5.3.7 CCR5 Receptor Antagonists
       5.3.8 Multi-class Combination Products/ Dual MOA products
   5.4 Competitive Landscape
   5.5 Company Profiles
       5.5.1 GlaxoSmithKline
       5.5.2 Shionogi
       5.5.3 Janssen-Cilag International NV
       5.5.4 VaxGen
       5.5.5 Tibotec Pharmaceuticals
       5.5.6 Merck
       5.5.7 Sanofi-Aventis
       5.5.8 Schering-Plough